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| INTRODUC TI ON
Congenital hemophilia is a genetic disorder that increases bleeding risk in affected individuals. The 2 major types of the bleeding disorder are hemophilia A, with a deficiency in coagulation factor VIII (FVIII), and hemophilia B, with a deficiency in factor IX (FIX). 1 In healthy subjects, FVIIIa (activated FVIII) acts as a cofactor for FIXa, serving to increase the affinity of FIXa for factor X (FX) by 10 000-fold. FIXa then converts FX to FXa. Both FVIII and FIX are parts of the intrinsic pathway of coagulation, which is impaired in patients with hemophilia. Based on the residual factor levels, the bleeding disorder can be categorized into severe (<1% residual factor activity), moderate (1%-5%), and mild (5%-40%). However, while residual FVIII/FIX activity is useful for the stratification of patients, the bleeding risk among these groups can vary considerably and is influenced by multiple factors such as genetic mutation types or von Willebrand factor levels. [2] [3] [4] [5] Individuals with hemophilia A or hemophilia B are more likely to have bleeding in the joints where tissue factor (TF) expression is considered low and weight/impact-induced biomechanical perturbation of the joint is high.
Conventional treatment for patients with hemophilia is the administration of intravenous factor replacements to restore their residual factor levels, and this can be done prophylactically or on demand.
One third of patients with severe hemophilia A develop neutralizing antibodies against FVIII and 1.5% to 3% of patients with hemophilia B develop FIX-neutralizing antibodies. These "inhibitor" patients are treated with bypassing agents such as activated prothrombin complex concentrates or recombinant FVIIa (rFVIIa). 6, 7 rFVIIa enhances FX activation through TF-dependent, cellular surface-dependent, and endothelial protein C receptor-dependent pathways. 8 A recent advance is the development of a bispecific antibody (emicizumab), which mimics FVIIIa function 9,10 by transiently binding FIXa and its substrate FX to mediate FXa generation. Emicizumab is advantageous, as it can be subcutaneously administered, has a long half-life (4 weeks), and no immunoglobulin G (IgG)-based immune responses have been reported so far. More importantly, the bispecific antibody can be used in patients with and without FVIII inhibitors. In addition to the traditional bypassing agents and FVIIIa-mimicking bispecific antibodies, several other novel agents are being investigated. For example, 3 monoclonal antibodies against tissue factor pathway inhibitor (TFPI) are currently in different phases of development. 11 Various in vitro models/assays have been used to study the effect of coagulation factor modulation on fibrin formation under flow conditions. [12] [13] [14] [15] [16] [17] [18] Sakurai et al 17 demonstrated that FVIII inhibition reduced fibrin accumulation, similar to the response observed in hemophilia A blood. Onasoga-Jarvis et al 15 reported that adding rFVIIa to FVIII-deficient blood could restore fibrin generation and potentially lead to a prothrombotic state. Swieringa et al 12 demonstrated that perfusion of FIX-deficient blood (5% FIX) over collagen/TF microposts led to impaired fibrin formation. Thomassen et al 14 showed that TFPI-α antagonism was able to increase fibrin formation in blood from both healthy donors and patients with hemophilia.
The determination of residual FVIII/FIX activity is assessed in the clinic using a static assay that uses plasma rather than whole blood. Microfluidic assays allow the phenotyping of whole blood from patients with hemophilia and provide a platform to assess the efficacy of various therapeutics under flow in a high-throughput fashion. 15, [19] [20] [21] [22] [23] [24] In such assays, whole blood is perfused over prothrombotic surfaces such as collagen or collagen/TF, and clot growth is measured. Blood from patients with severe hemophilia displays a defect in both platelet deposition and fibrin formation under flow.
In contrast, blood from patients with moderate and mild hemophilia displays relatively normal platelet deposition with deficits in fibrin formation. Patient recruitment, variability in their clinical presentation, and interference from prophylactic products all pose significant challenges to the development of whole blood microfluidic assays to study drug potency or mechanism of action on a background of hemophilia. As more patients switch to novel therapeutics like emicizumab with a longer half-life (4 weeks as opposed to 1 week for the traditional FVIII products), drug testing in patient blood without interference from prophylactics may become increasingly difficult. Therefore, it would be useful to recapitulate the hemophilic phenotypes ex vivo using treated blood from healthy donors. Such hemophilia models allow significantly greater throughput and standardization compared to using blood from patients with hemophilia. Donated blood from healthy donors is more readily available and excludes the potential interference of other drugs. We present 2 hemophilia microfluidic assays using healthy adult blood to study the effect of bypassing agents. The use of highly diluted TF or FXIa in the triggering surface allowed the dose-response testing of anti-TFPI, emicizumab, and a patient-derived FVIII-neutralizing antibody.
| METHODS

| Blood collection
Whole blood (1 mL) was collected into a syringe containing corn trypsin inhibitor (CTI, 4 µg/mL) to lightly suppress contact pathway activation of FXIIa during sample collection and handling. Whole blood was subjected to microfluidic assay within 10 minutes of collection.
Essentials
• Limited availability of patient samples is a major challenge for hemophilia drug action studies.
• Microfluidic assays using blood from healthy donors were developed to phenocopy hemophilia.
• A hemophilia A assay demonstrated the potency of emicizumab on collagen/FXIa-coated surfaces.
• A hemophilia B assay demonstrated potency of anti-TFPI on collagen/TF-coated surfaces.
| Reagents
Reagents were obtained as follows: Alexa Fluor 488 conjugated anti-human CD61 (Bio-Rad), AF647 conjugated human fibrinogen (ThermoFisher Scientific), type I fibrillar collagen (Chronolog), Dade Innovin lipidated tissue factor (TF, Siemens), CTI and FXIa (Haematologic Technologies), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Fisher Scientific), Sigmacote (Sigma), Anti-FVIII (4A4) and anti-FIX (BC2; Green Mountain Antibodies), Anti-TFPI (gA200 hIgG1, Bayer, Whippany), bispecific antibody (emicizumab), reFIX-V181T variant, 25 and a recombinant rIgG4 containing complementarity-determining regions originally derived from a patient (NB41, as described in van den Brink 26 ).
| Microfluidic clotting assay
Whole blood was perfused over a patterned prothrombotic surface to trigger clot formation in microfluidic devices at 1 µL/min per channel. A single 250-µm-wide channel polydimethylsiloxane (PDMS) patterning device was vacuum-sealed to a Sigmacotetreated glass slide, as previously described. 27, 28 A total of 5 µL of fibrillar collagen was perfused through the channel to pattern a stripe of aligned collagen fibers. For TF-dependent assays, this step was followed by TF perfusion (20 nmol/L or 1 nmol/L, 5 µL) and incubated under static conditions for 30 minutes to allow binding to collagen. For intrinsic pathway-dependent assays, FXIa (4.9 µg/ mL, 5 µL) was used instead of TF. The channel was then rinsed with 20 µL of 1% bovine serum albumin. The patterning device was then replaced by an 8-channel PDMS device positioned perpendicularly to the surface pattern stripe to form 8 uniformly distributed prothrombotic patches (250 µm × 250 µm) ( Figure S1A ). Anti-FVIII (4A4) and patient-derived NB41 were used to inhibit FVIII activity in healthy blood to recapitulate hemophilia A clotting defect. Anti-FIX (BC2) and reFIX-V181T variant were used to inhibit FIX activity in healthy blood to recapitulate hemophilia B clotting defect.
| Imaging
Platelet and fibrin were detected by an epifluorescence microscopy (IX81; Olympus America Inc.) and a charge-coupled device camera (Hamamatsu, Bridgewater, NJ, USA). A 10X objective/0.30NA was used in all of the experiments. ImageJ (NIH, Bethesda, MD, USA) was used to analyze acquired images. The mean fluorescent intensity was measured over the central 75% of the channel to eliminate side-wall effects. The fluorescence values were background-corrected by subtracting the signals at the first time point. 
| Statistical analysis
| RESULTS
| Hemophilia A model
A commercially available murine FVIII-neutralizing antibody (anti-FVIII) was added to healthy blood to recapitulate the hemophilia A phenotype in our device ( Figure 1A) . We have previously shown that whole blood perfused over collagen/TF ( Figure 1B ) could be used to study TF-dependent therapeutics. 19 FVIII inhibition did not result in marked decreases in platelet accumulation ( Figure 1D ), but all 3 doses of anti-FVIII significantly reduced fibrin generation. In the presence of TF, the effect of FVIII inhibition only started to manifest at later time points. We have previously used collagen or collagen/kaolin to activate the contact pathway 24 ; however, factors such as device surface treatment and incubation time could influence the onset and the extent of contact activation. Here, we present a modified assay using collagen/FXIa as the surface trigger ( Figure 1C ) to activate the intrinsic pathway ( Figure S5 ). On collagen/FXIa surfaces, FVIII inhibition resulted in a slight reduction in platelet deposition ( Figure 1F ) after 7 minutes. More importantly, anti-FVIII at concentrations ≥ 25 µg/mL abolished fibrin generation ( Figure 1G ). Platelet deposition in FVIII-inhibited blood ( Figure 1F) began to deviate from the control shortly after onset of fibrin polymerization ( Figure 1G ). We also treated healthy blood with a neutralizing FVIII-binding antibody (15 µg/mL) derived from patients with hemophilia A (Figure 1H ,I), and similar results were observed. that demonstrated a striking 554.5% increase in fibrin with drug. In addition to emicizumab, Advate also restored fibrin generation in blood of the patient with hemophilia A (Figures S2 and S3 ).
| The effect of an FVIIIa-mimetic bispecific antibody in hemophilia A assay
| Hemophilia B model
To Figure 5A ) and fibrin generation ( Figure 5B) . The FIX variant also reduced platelet accumulation ( Figure 5C ) and fibrin polymerization ( Figure 5D ) on collagen surfaces with diluted TF (20-fold TF dilution factor). Although less fibrin was made at low TF in comparison to the high TF condition, the 95% inhibition by reFIX-V181T was more pronounced on low TF surfaces providing a larger dynamic range for the assay.
| The effect of anti-TFPI in hemophilia B assay
The use of reFIX-V181T to recreate hemophilia B phenotype allowed us to test the effect of bypassing agents such as anti-TFPI.
The control experiment in Figure 5 range for subsequent figures: Low TF was then used in Figure 6 .
Adding anti-TFPI did not significantly affect platelet accumulation ( Figure 6A ) in healthy adult blood (no reFIX-V181T present) on low TF surfaces likely because collagen alone was a potent platelet agonist. However, all 3 doses of anti-TFPI significantly enhanced fibrin polymerization ( Figure 6B) to the same level. Also, the control channels occluded by 8 minutes. When healthy blood was dosed with 50 µg/mL of reFIX-V181T, anti-TFPI (≤12 µg/mL) dose-dependently restored platelet deposition ( Figure 6C ) and increased fibrin polymerization ( Figure 6D ). This was in agreement with results of concizumab from a previous clinical trial. 31 
| DISCUSSION
Here, we report ex vivo hemophilia models that allow the assessment of novel FVIII/FIX replacements and bypassing agents. In the past, we have used blood inhibited with low levels of CTI to investigate hemophilia A phenotypes on collagen/±TF surfaces.
Consistent with the previous observation that high levels of TF can partially compensate for the FVIII deficiency, 19 adding the anti-FVIII inhibitory antibody to the whole blood from healthy individuals reduced but did not abolish platelet and fibrin deposition.
Platelet accumulation was unaffected possibly due to the strong F I G U R E 6 Testing anti-TFPI in hemophilia B assay. The effect of anti-TFPI on platelet and fibrin deposition were investigated in healthy blood (A, B) and hemophilia B mimetic blood (C, D). Anti-TFPI not only restored coagulation in hemophilia A model (D), but it also has a procoagulant effect in blood with normal FIX activity (B). This is in agreement with results of another anti-TFPI (concizumab) from a previous clinical trial. 34 Differences between control and treated groups were analyzed with 2-way analysis of variance with Bonferroni posttest. *P < 0.05. Shaded areas represent standard deviation. CTI, corn trypsin inhibitor; FI, fluorescence intensity; n.s., nonsignificant; TF, tissue factor; TFPI, tissue factor pathway inhibitor; WB, whole blood activation by the collagen trigger and ADP/thromboxane A 2 release. While the TF-dependent pathway alone was able to generate enough thrombin for fibrin polymerization, all 3 doses of anti-FVIII reduced fibrin generation after 5 minutes due to the defect in the FXI-thrombin feedback loop. 32 This reduction in the late-stage fibrin generation was similar to the previously reported results for FXI-inhibited clot formation. 33 Traditionally, kaolin is used to study TF-independent clotting in healthy/hemophilic blood assays. Here, we developed a new method using collagen/FXIa surfaces to potently and locally activate the intrinsic pathway. The use of FXIa bypasses the need for FXII activation; therefore, blood can be collected in high levels of CTI (40 µg/ mL), which alleviates the need to start the assay right after the blood collection. In Figure 4 , all 3 concentrations of the murine FVIIIneutralizing antibody (4A4) abolished fibrin generation on collagen/ FXIa within the experimental time frame. This was also true for the recombinant IgG4 NM41, which was derived from an inhibitor patient. 26 Because collagen alone was potent enough to drive platelet aggregation to full occlusion, it was difficult to capture the effect of anti-FVIII on platelets. In contrast, the sensitivity and the large dynamic range of fibrin polymerization makes the system a good platform to study novel therapeutics such as FVIII-mimetics like bispecific antibodies in a low-TF environment. Using this collagen/ FXIa-based assay, we demonstrated that Advate and emicizumab were able to restore coagulation in hemophilia A blood, therefore recapitulating the situation in vivo.
We also quantitatively validated our microfluidic hemophilia A For anti-FVIII > 25 µg/mL, fibrin polymerization was abolished on collagen + FXIa. Similarly, FIX-V181T > 50 µg/mL caused a very substantial reduction of fibrin generation on collagen + low TF. This extent of coagulation defect was equivalent to observations of fibrin formation previously reported for severe FVIII-and FIX-deficient patients, 19, 24 where residual activities of FVIII or FIX were <1% of normal.
In conclusion, we have developed 2 hemophilia assays that mimic hemophilia A and hemophilia B phenotypes through dosing readily accessible healthy blood with a FVIII-neutralizing antibody and a recombinant FIX variant, respectively. The surface trigger concentration is adjustable and either collagen/TF or collagen/FXIa can be used depending on the pathway of interest. While factor inhibition is what enables us to phenocopy hemophilia clotting profile, the 2 highly sensitive models allow for high-throughput evaluation of drug responses. A limitation of the models is that they cannot be used to test traditional factor replacement therapeutics because the FVIIIneutralizing antibody and the recombinant FIX variant will interfere with the activity of the exogenous factors. Nonetheless, the hemophilia assays could enable rapid screening/evaluation of novel hemophilic agents in whole blood under flow in a high-throughput fashion, which helps narrow the therapeutic candidates before testing them in hemophilic patient blood. The hemophilia assays also have the added advantage of allowing side-by-side comparisons to clotting at healthy factor levels. Future work is needed to recapitulate different hemophilia severities/residual factor levels using different anti-FVIII/reFIX doses. The platelet agonist on the prothrombotic surface can be optimized to increase the dynamic range for platelet deposition by reducing thrombin-independent platelet activation/ aggregation. Alternatively, as fibrin generation is more sensitive to factor level changes, the TF trigger alone may be used to initiate coagulation. 34 In addition, patient-derived neutralizing antibodies and factor variants can be explored to predict the effect of therapeutics in patients with hemophilia with the specific inhibitors/mutations.
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